93. 原発性胆汁性胆管炎 Primary biliary cholangitis Clinical trials / Disease details
臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04604652 (ClinicalTrials.gov) | May 27, 2021 | 16/10/2020 | Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis | A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC | Primary Biliary Cholangitis;Primary Biliary Cirrhosis;Cholangitis;Cholestasis;Biliary Tract Diseases;Bile Duct Stricture | Drug: HTD1801 (BUDCA) | HighTide Biopharma Pty Ltd | NULL | Recruiting | 18 Years | 75 Years | All | 30 | Phase 2 | United States |